Day Two, 24 August 2012: Drug Discovery and development

Please enable javascript to see more information on speakers

	MORNING MODULE: DRUG DISCOVERY AND DEVELOPMENT
09.00	Opening remarks from the Chair Dr Aamir Shaikh Dr. Aamir Shaikh obtained his graduate medical degree (MBBS) in 1992, his post-graduate Diploma in Pharmaceutical Business Management (DPBM) in 1995, and his post-graduate medical degree (MD Pharmacology) in 1997. He began his career as a... more.. › Dr Aamir Shaikh, Founder, Assansa
09.10	Keynote: Opportunities for drug discovery and development in Australia Dr Andrew Harvey Dr Andrew Harvey joined the chemistry group at Bionomics in 2007 and has led the group in the Multiple Sclerosis collaboration with European pharmaceutical company, Merck Serono, since the collaboration began in June 2008. He played a leading... more.. › Dr Andrew Harvey, VP Drug Discovery, Bionomics
09.40	Utilising non-diluting funding to progress drug discovery and development Dr Jane Ryan Dr Ryan has many years of international experience in the Pharmaceutical/Biotechnology Industry where she managed research and development programs, as well as having key roles in business development and alliance management. Dr Ryan is currently... more.. › Dr Jane Ryan, Vice President, Product Development and Strategic Marketing, Biota
10.10	How to successfully commercialise drug discovery platforms through alliances Mr Nick Woolf Mr Woolf is an accomplished biotechnology professional with 18 years’ experience in the industry, equity research and investment banking. He was formerly Chief Business Officer and Executive Director of Oxford BioMedica, a London-listed... more.. › Mr Nick Woolf, CFO, VP Corporate Development, Phylogica
10.40	Morning Refreshments
11.20	Exploring innovative business models to meet evolving R&D challenges Dr Daniel Grant Dan Grant is the Head of Pfizer’s External Research and Development Innovation (ERDI) group for Australia, New Zealand and Singapore. He is responsible for identifying, evaluating and managing collaborative and licensing opportunities that align... more.. › Dr Daniel Grant, Director and Head, External R&D, Pfizer
11.50	Panel: How pharma and biotech can work together in drug discovery and development Dr Jane Ryan Dr Ryan has many years of international experience in the Pharmaceutical/Biotechnology Industry where she managed research and development programs, as well as having key roles in business development and alliance management. Dr Ryan is currently... more.. Mr Nick Woolf Mr Woolf is an accomplished biotechnology professional with 18 years’ experience in the industry, equity research and investment banking. He was formerly Chief Business Officer and Executive Director of Oxford BioMedica, a London-listed... more.. Dr Andrew Harvey Dr Andrew Harvey joined the chemistry group at Bionomics in 2007 and has led the group in the Multiple Sclerosis collaboration with European pharmaceutical company, Merck Serono, since the collaboration began in June 2008. He played a leading... more.. Dr Daniel Grant Dan Grant is the Head of Pfizer’s External Research and Development Innovation (ERDI) group for Australia, New Zealand and Singapore. He is responsible for identifying, evaluating and managing collaborative and licensing opportunities that align... more.. › Dr Jane Ryan, Vice President, Product Development and Strategic Marketing, Biota › Mr Nick Woolf, CFO, VP Corporate Development, Phylogica › Dr Andrew Harvey, VP Drug Discovery, Bionomics › Dr Daniel Grant, Director and Head, External R&D, Pfizer
12.30	Networking Lunch